|
|
 |
|
Viewing report
|
|
|
|
Clinical Proteomics: Rethinking Approaches to Protein Biomarker Discovery
Decision Resources, Inc, May 2007, Pages: 26
Protein biomarkers are appealing to drug developers because they can be used early in the drug research pipeline, which allows early elimination of ineffective or toxic compounds. Although the promise of these biomarkers is clear, the path to successful implementation of protein biomarkers is not. Perhaps the discovery-based approach is not the best way to tap the potential of protein biomarkers.
Get the Answers You Need to Shape Your Strategy
- Despite scientific advancements, protein biomarker discovery is slowing. What are the challenges facing companies and researchers that are hindering the discovery process?
- Researchers are rethinking the discovery-based approach. What other options and innovations are available? What companies are leading the way?
- The future of protein biomarkers is extremely promising for a multitude of businesses. What benefits are available for technology vendors, Big Pharma companies, researchers, and regulatory agencies? Can collaboration between any or all of these stakeholders ensure the success of protein biomarkers?
Scope
- Proteomics technologies: 2D PAGE, mass spectrometry, antibody micro arrays, micro fluidics, label-free technologies.
- Alternatives to discovery-based approach: hypothesis-based approach, engineering better biomarkers, systems biology.
- Major players in protein biomarker discovery: Bayer, Eli Lilly, Novartis, Pfizer, Roche.
- Outlook: The path toward successful protein biomarker discovery may include multiplexing strategies, collaborations among researchers and developers, and support from regulatory bodies.
|
|
|
|
